Listed by the USPTO as CHATTIN, AMY MARIE
Tech Center 1600 • Art Units: 1637 1642 1643 1644 1646
This examiner grants 71% of resolved cases
CHATTIN, AMY MARIE is a USPTO patent examiner in Tech Center 1600 and Art Unit 1637. The profile includes 56 resolved cases, an allowance rate of 71.4%, and a median of 1380 days to allowance. Interview lift is 45.9%, showing a substantial association between interviews and allowance outcomes.
The listed companies are The Regents of the University of California, Genentech Inc., and Hoffmann-La Roche Inc. The leading firms are NORTON ROSE FULBRIGHT US LLP, WC&F IP, and Casimir Jones, S.C. The allowance rate provides useful historical context, while the 45.9% interview lift supports making interviews a deliberate part of response planning when issues can be resolved through discussion. The 56-case record is informative but limited, so practitioners should connect the statistics to the application’s technology and claim structure. The 1380-day median requires long-range docket management.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18612141 | USES OF IL-13 ANTAGONISTS FOR TREATING ATOPIC DERMATITIS | Non-Final OA | GENENTECH, INC. |
| 18553143 | ANTIBODIES AGAINST CLEAVED CDCP1 AND USES THEREOF | Non-Final OA | The Regents of the University of California |
| 18248189 | MOTIF NEOEPITOPES FOR CANCER IMMUNOTHERAPY | Final Rejection | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA |
| 17773283 | DEGRADATION OF SURFACE PROTEINS USING BISPECIFIC BINDING AGENT | Non-Final OA | The Regents of the University of California |
| 18066529 | PROTEASE-ACTIVATED T CELL BISPECIFIC ANTIBODIES | Non-Final OA | Hoffmann-La Roche Inc. |
| 19548088 | METHODS FOR TREATING OR PREVENTING ASTHMA BY ADMINISTERING AN IL-4R ANTAGONIST | Non-Final OA | REGENERON PHARMACEUTICALS, INC. |
| 18252928 | ANTI-CD6 ANTIBODY CONJUGATES FOR TREATING T-CELL MEDIATED DISORDERS AND T-CELL LYMPHOMA/LEUKEMIA | Final Rejection | The Cleveland Clinic Foundation |
| 17765585 | METHODS AND COMBINATIONS FOR THE TREATMENT OF CANCER USING IMMUNE CHECKPOINT INHIBITOR ANTIBODIES | Final Rejection | ASTRAZENECA AB |
| 18481725 | COMPOSITIONS AND METHODS OF TREATING CANCER WITH CHIMERIC ANTIGEN RECEPTORS TARGETING CLAUDIN 18.2 | Non-Final OA | MEDIMMUNE, LLC |
| 17802794 | ANTIGEN-PRESENTING EXTRACELLULAR VESICLES, COMPOSITION CONTAINING SAME, AND METHOD FOR PRODUCTION THEREOF | Final Rejection | NISSAN CHEMICAL CORPORATION |
| 18324012 | COMPOSITIONS AND METHODS FOR PREPARING ENGINEERED LYMPHOCYTES FOR CELL THERAPY | Final Rejection | Kite Pharma, Inc. |
| 17787094 | MULTI-SPECIFIC ANTIBODIES | Non-Final OA | UCB BIOPHARMA SRL |
| 18686868 | CHIMERIC ANTIGEN RECEPTOR (CAR) T CELL THERAPY PLATFORM | Non-Final OA | The Research Institute at Nationwide Children's Hospital |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy71.4% of resolved applications examined by Amy Marie Chattin were allowed (56 resolved cases), compared with 44.9% across Art Unit 1637 over the last five years.
This examiner's interview lift is +45.9 percentage points: the difference in allowance rate between resolved applications that had an examiner interview and those that did not.
Applications allowed by Amy Marie Chattin took 1,380 days on average from filing to allowance.
Amy Marie Chattin examines applications in Art Unit 1637 in Tech Center 1600 (Biotechnology & Pharmaceuticals).